Abstract
This short review outlines the scientific progression from the neuropeptide vasoactive intestinal peptide as a neuroprotective agent that acts through glial cells to increase and modulate the synthesis and secretion of novel neuroprotective substances. Recent development in the studies on activity-dependent neuroprotective protein (ADNP) and activitydependent neurotrophic factor (ADNF) and short peptide derivatives of these proteins, ADNF-9 and NAP suggest that these peptides are neurotrophic and promote neurite outgrowth. These short peptides hold promise in future neuroprotective/ neurotrophic drug development. Clinical development of NAP is currently in progress by Allon Therapeutics, Inc.
Keywords: Vasoactive intestinal peptide (VIP), ciliary neurotrophic factor (CNTF), ADNF-9, neuroprotective, expression
Current Alzheimer Research
Title: Neurotrophic Effects of the Peptide NAP: A Novel Neuroprotective Drug Candidate
Volume: 3 Issue: 3
Author(s): Illana Gozes and Irit Spivak-Pohis
Affiliation:
Keywords: Vasoactive intestinal peptide (VIP), ciliary neurotrophic factor (CNTF), ADNF-9, neuroprotective, expression
Abstract: This short review outlines the scientific progression from the neuropeptide vasoactive intestinal peptide as a neuroprotective agent that acts through glial cells to increase and modulate the synthesis and secretion of novel neuroprotective substances. Recent development in the studies on activity-dependent neuroprotective protein (ADNP) and activitydependent neurotrophic factor (ADNF) and short peptide derivatives of these proteins, ADNF-9 and NAP suggest that these peptides are neurotrophic and promote neurite outgrowth. These short peptides hold promise in future neuroprotective/ neurotrophic drug development. Clinical development of NAP is currently in progress by Allon Therapeutics, Inc.
Export Options
About this article
Cite this article as:
Gozes Illana and Spivak-Pohis Irit, Neurotrophic Effects of the Peptide NAP: A Novel Neuroprotective Drug Candidate, Current Alzheimer Research 2006; 3 (3) . https://dx.doi.org/10.2174/156720506777632790
DOI https://dx.doi.org/10.2174/156720506777632790 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
γ-Secretase as a Therapeutic Target for the Treatment of Alzheimers Disease
Current Pharmaceutical Design Synthesis and Biological Evaluation of Novel Bioisosteric Analogues of Dimebon™
Letters in Drug Design & Discovery Update on Myositis Therapy: From Today’s Standards to Tomorrow’s Possibilities
Current Pharmaceutical Design The Neurotrophins and Their Role in Alzheimers Disease
Current Neuropharmacology FTD and ALS: A Tale of Two Diseases
Current Alzheimer Research Therapeutic Targeting of Epigenetic Components in Amyotrophic Lateral Sclerosis (ALS)
Current Medicinal Chemistry Recent Advances in Three-Component Cyclocondensation of Dimedone with Aldehydes and Malononitrile for Construction of Tetrahydrobenzo[b]pyrans Using Organocatalysts
Current Organic Synthesis Induced Pluripotent Stem Cells and Their Potential for Basic and Clinical Sciences
Current Cardiology Reviews Editorial [Hot Topic: Drug Discovery for CNS Disorders: From Bench to Bedside (Guest Editor: Tiago Fleming Outeiro)]
CNS & Neurological Disorders - Drug Targets Pathogenic Mechanisms and Therapeutic Strategies in Spinobulbar Muscular Atrophy
CNS & Neurological Disorders - Drug Targets Gene Therapy for Parkinsons and Alzheimers Diseases: from the Bench to Clinical Trials
Current Pharmaceutical Design Current Clinical Applications of Botulinum Toxin
Current Pharmaceutical Design Diagnosis, Pathogenesis and Therapeutic Targets in Amyotrophic Lateral Sclerosis
CNS & Neurological Disorders - Drug Targets MicroRNAs: Newcomers into the ALS Picture
CNS & Neurological Disorders - Drug Targets Past, Present and Future Therapeutics for Cerebellar Ataxias
Current Neuropharmacology Oxidative Stress and Antioxidant Potential of One Hundred Medicinal Plants
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: MiRNAcles in the Brain: What to Wish and What to Fear)
CNS & Neurological Disorders - Drug Targets Use of Peripheral Blood Stem Cells in Tissue Engineering
Current Tissue Engineering (Discontinued) An Agathokakological Tale of Δ<sup>9</sup>-THC: Exploration of Possible Biological Targets
Current Drug Targets Discovering New Treatments for Alzheimer's Disease by Repurposing Approved Medications
Current Topics in Medicinal Chemistry